Modulation of wnt signalling in corneal disorders
OwnerPriya HANDA, Sungjin LEE +4inventors
InventorsPriya HANDA, Sungjin LEE, Yang LI, Laura SANMAN, Geertrui VANHOVE, Wen-Chen YEH
Life of this patent
Estimating the term…
Abstract
Current treatments for corneal disorders, also called keratopathies, depend on the stage of the keratopathy. For mild keratopathies, supportive treatments such as saline eyedrops may be sufficient to ameliorate symptoms. The present disclosure provides methods of treating corneal disorders with modulators of the WNT signaling pathway. More particularly, provided are treatments for cornea epithelial and/or endothelial injuries, defects, deficiencies, and dystrophies. Further provided are methods of dosing and pharmaceutical compositions for the treatment of corneal disorders.
Claims29
A method of treating a keratopathy in a subject, comprising administering an engineered WNT signaling modulator to the subject, wherein the modulator is an engineered WNT agonist or an engineered WNT antagonist.
-3. (canceled)
(canceled)
-13. (canceled)
(canceled)
-19. (canceled)
(canceled)
-25. (canceled)
A method of increasing cell yield of mammalian cornea epithelium and/or endothelium cells grown ex vivo prior or post cornea or corneal cell transplant, comprising:
- treating a mammalian donor cornea or isolated mammalian cornea cells with an engineered WNT signaling modulator, wherein the modulator is an engineered WNT agonist or an engineered WNT antagonist.
-29. (canceled)
-42. (canceled)
Dependencies are inferred from the claim text.